Creabilis Therapeutics Appoints Anthony Wilson as its New Chief Executive Officer
Creabilis Therapeutics SpA announced the appointment of Tony Wilson as Chief Executive Officer with immediate effect. Mr Wilson brings to Creabilis a broad knowledge of the biotechnology and pharmaceutical industry combined with first hand experience of the dermatology sector.
He has over 25 years industry experience gained for the most part at Leo Pharmaceuticals a company engaged in clinical research, manufacture, marketing and sales of Leo Group products in the UK. While at Leo Pharmaceuticals Mr Wilson has been involved in the development and marketing of Dovonex and Dovobet, two of the most successful products in the history of dermatology.
Mr Wilson joins Creabilis from Janus Pharmaceuticals, Inc. a US-headquartered dermatology company with its lead product, luliconazole, a novel topical prescription anti-fungal product, in late stage development in the USA and Europe. Prior to that he was co-founder and CEO of Salveo Pharmaceuticals Ltd. Salveo was a speciality pharmaceutical company whose objectives were to acquire and market dermatology products in Europe.
Other news from the department price development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Emergent BioSolutions Announces Appointment of Ronald Richard to the Board of Directors

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Bayer: Supervisory Board extends CEO Werner Baumann’s - Contract until the end of April 2024

Restoring vision by gene therapy - Latest scientific findings give hope for people with incurable retinal degeneration
Pantec Biosolutions receives ISO 13485 certification
Stora Enso awarded as Finland’s most startup-friendly company
Genetic screening before embryo transfer fails to improve the chance of a baby

Hero proteins are here to save other proteins - New group of proteins prevent dangerous clumps associated with neurodegenerative diseases
Applied DNA Sciences collaborates with Advanced Coding Systems to produce DNA-embedded microwires
